Why Lasmiditan?

Lasmiditan is a member of a novel drug class called "ditans".

Lasmiditan penetrates the central nervous system (CNS) and selectively targets 5-HT1F receptors expressed in the trigeminal nerve pathway.

Learn More About Lasmiditan

Lasmiditan does not interact with vasoconstrictor 5-HT1B/1D receptors activated by triptans.

No evidence of drug-related cardiovascular adverse effects or chest symptoms in the previous six clinical studies.

Learn More About Lasmiditan

Six clinical studies provide Proof of Concept in the acute treatment of migraine attacks.

Learn More About Lasmiditan

Development Plan

Phase 2b Proof of concept

Lasmiditan SP-Agreement

Meet CoLucid

Nadia Rupniak

Vice President, Research and Development

Nadia Rupniak, Ph.D.

A neuroscientist with 20 years experience, Nadia is best known as the champion for Merck's Substance P (NK1) receptor antagonist research and…

Read More Meet The Others

About Migraines

Partners

A migraine is a painful neurological condition, of which the most common symptom is an intense and disabling headache.

Learn More About Migraines
Partners